While endocrine abnormalities in Transfusion-Dependent Thalassemia (TDT) are well-documented, the clinical interplay between oxidative stress, iron burden, and chelation therapy remains unclear. To address this gap, Mishra et al. evaluated oxidative stress profiles and the impact of various chelation regimens to determine the predictive value of these biomarkers for early, multi-axis endocrine dysfunction.
Therefore, the 18-month prospective, comparative study evaluated 53 patients with Transfusion-Dependent Thalassemia (TDT) and 29 matched healthy controls. The study quantified oxidative stress markers (MDA, SOD, GPx, catalase, TAC), serum ferritin, and various endocrine parameters. Patients were clinically stratified by their chelation regimen (deferasirox, deferoxamine, or combination therapy), and multivariate regression analysis was utilized to identify independent predictors of early endocrine dysfunction.
Key Clinical Findings of the study Includes:
Elevated Oxidative Stress: Research showed that TDT patients demonstrated significantly higher MDA levels and substantially reduced antioxidant enzyme activity when directly compared with healthy controls (p < 0.001).
Chelation Therapy Efficacy: Interventions indicated that combination chelation therapy was successfully associated with lower serum ferritin levels and highly improved antioxidant profiles relative to isolated monotherapy regimens (p < 0.05).
Biomarker Correlations: Findings demonstrated that oxidative stress markers significantly correlated with serum ferritin and multiple critical endocrine parameters, including thyroid-stimulating hormone (TSH), growth velocity, pubertal staging, and fasting plasma glucose.
Predictors of Dysfunction: Analysis revealed that elevated MDA and diminished TAC functioned as powerful independent predictors for the early onset of endocrine impairment in these vulnerable patients.
The results suggest that persistent oxidative stress plays a definitively central role in mediating iron-induced multi-axis endocrine dysfunction in individuals living with TDT. Furthermore, specific oxidative biomarkers may reliably serve as early predictive indicators to accurately gauge both endocrine impairment and ongoing therapeutic responses.
Thus, the study concludes clinicians should consider integrating predictive oxidative biomarkers, notably MDA and TAC, into routine patient monitoring and the ongoing optimization of personalized chelation strategies to better manage long-term morbidities.
While the current observational framework provides valuable institutional insights, broader multicenter research could smoothly build upon these fundamental findings to fully establish standardized, universally applicable protocols for utilizing oxidative stress monitoring in diverse clinical settings.
Reference
Mishra, S., Singhal, A., Mishra, N., Shukla, S., Singh, B., & Verma, N. (2026). Prevalence and Clinical Profile of Thyroid Dysfunction in Transfusion-Dependent Thalassemia: A Prospective Observational Study in a Tertiary Care Center. Indian Journal of Hematology
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.